文档介绍：Chinese-German Journal of Clinical Oncology September 2012, Vol. 11, No. 9, P539–P543
DOI -012-1023-8
Treatment for triple-negative breast cancer
Xuebing Shi, Lu Wang
Department of Medical Oncology, Yijishan Hospital of Wannan Medical College, Wuhu 241000, China
Received: 18 May 2012 / Revised: 19 July 2012 / Accepted: 25 July 2012
© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2012
Abstract Triple-negative breast cancers (TNBCs) neither express estrogen receptor and progesterone receptor nor over-
express human epidermal growth factor receptor-2. Because of the special molecular features, triple-negative breast cancer
is not either sensitive to endocrine therapy or targeted therapy of trastuzumab. There has not been standard treatment
regimen for triple-negative breast cancer yet and chemotherapy has still been the chief therapy currently. However, with the
great progress of oncology and molecular biology, the understanding of the natural history, pathophysiology and molecular
features of this disease has been greatly improved, and a growing number of novel and effective therapies and discoveries of
new biological targets for this phenotype of breast cancers have been reported, which provide new insights into therapeutic
strategies for the women suffering from it.
Key words triple-negativ